Merck, Pfizer’s Bavencio flunks head and neck cancer trialMerck KGaA and Pfizer’s checkpoint inhibitor Bavencio has failed a phase 3 trial in head and neck cancer, Share XMerck, Pfizer’s Bavencio flunks head and neck cancer trialhttps://pharmaphorum.com/news/merck-pfizers-bavencio-flunks-head-and-neck-cancer-trial/
AZ’s cediranib falls short again in ovarian cancer combinationAstraZeneca and Merck & Co’s latest attempt to revive an old pipeline drug cediranib has failed as it Share XAZ’s cediranib falls short again in ovarian cancer combinationhttps://pharmaphorum.com/news/azs-cediranib-falls-short-again-in-ovarian-cancer-combination/
Takeda’s Ninlaro falls short in first line multiple myelomaTakeda’s Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgene’s Revlimid Share XTakeda’s Ninlaro falls short in first line multiple myelomahttps://pharmaphorum.com/news/takedas-ninlaro-falls-short-in-first-line-multiple-myeloma/
Amgen/Allergan’s rituximab biosimilar could be $4bn blockbusterTen drugs filed with regulators have potential to become billion-sellers by 2025 according to new research, with a near-copy Share XAmgen/Allergan’s rituximab biosimilar could be $4bn blockbusterhttps://pharmaphorum.com/news/amgen-allergans-rituximab-biosimilar-could-be-4bn-blockbuster/
Janssen antibody could be lung cancer breakthroughThe FDA thinks a dual-target antibody from Janssen could set new standards in treatment for certain patients with Share XJanssen antibody could be lung cancer breakthroughhttps://pharmaphorum.com/news/janssen-genmab-antibody-could-be-lung-cancer-breakthrough/
BMS/AbbVie’s combo falls short in untreated multiple myeloma trialAdding Bristol-Myers Squibb/AbbVie’s Empliciti to Revlimid, developed by BMS’ recently acquired Celgene unit, does not improve survival in Share XBMS/AbbVie’s combo falls short in untreated multiple myeloma trialhttps://pharmaphorum.com/news/bms-abbvies-combo-falls-short-in-untreated-multiple-myeloma-trial/
Christie Hospital scheme aims to improve patient access to cancer trialsThe Christie NHS Foundation Trust has joined forces with a patient recruitment specialist to try to solve the Share XChristie Hospital scheme aims to improve patient access to cancer trialshttps://pharmaphorum.com/news/christie-hospital-scheme-aims-to-improve-patient-access-to-cancer-trials/
Sanofi gets first OK for isatuximab for myeloma, challenging J&J’s DarzalexSanofi has claimed FDA approval for its anti-CD38 drug isatuximab as a third-line treatment for multiple myeloma, becoming Share XSanofi gets first OK for isatuximab for myeloma, challenging J&J’s Darzalexhttps://pharmaphorum.com/news/sanofi-gets-first-ok-for-isatuximab-for-myeloma-challenging-jjs-darzalex/
AbbVie/Roche’s Venclexta fails in confirmatory AML trialAbbVie and Roche’s Venclexta has failed to significantly improve overall survival in an acute myeloid leukaemia (AML) trial Share XAbbVie/Roche’s Venclexta fails in confirmatory AML trialhttps://pharmaphorum.com/news/abbvie-roches-venclexta-fails-in-confirmatory-aml-trial/
Gilead to buy immuno-oncology firm Forty Seven for $4.9bnGilead is to buy immuno-oncology firm Forty Seven for $4.9 billion, adding an antibody targeting several blood cancers Share XGilead to buy immuno-oncology firm Forty Seven for $4.9bnhttps://pharmaphorum.com/news/gilead-to-buy-immuno-oncology-firm-forty-seven-for-4-9bn/
Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdictEli Lilly’s cancer drug Cyramza has inched closer to a new indication in first-line non-small cell lung cancer Share XLilly’s Cyramza closer to first-line lung cancer use after ODAC verdicthttps://pharmaphorum.com/news/lilly-closes-on-first-line-lung-cancer-use-after-odac-verdict/
NICE backs Celgene’s Revlimid for chemo-free lymphoma therapyNICE has backed Celgene’s Revlimid for routine NHS use in another indication, follicular lymphoma, as part of a Share XNICE backs Celgene’s Revlimid for chemo-free lymphoma therapyhttps://pharmaphorum.com/news/embargo-001-27-feb-nice-backs-celgenes-revlimid-for-chemo-free-lymphoma-therapy/
NICE rejects Roche’s Polivy combination in advanced lymphomaEngland’s NHS should not fund Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine for adults with Share XNICE rejects Roche’s Polivy combination in advanced lymphomahttps://pharmaphorum.com/news/nice-rejects-roches-polivy/
Roche hops on Bicycle’s drug discovery platform for cancerRoche’s recent spate of billion-dollar plus alliances has continued with a deal with UK biotech Bicycle Therapeutics – Share XRoche hops on Bicycle’s drug discovery platform for cancerhttps://pharmaphorum.com/news/roche-hops-on-bicycles-drug-discovery-platform-for-cancer/
GSK begins cancer cell therapy tie-up with ImmaticsCancer biotech Immatics has begun a collaboration with GlaxoSmithKline to develop novel therapies built around its T-cell-based technology. Share XGSK begins cancer cell therapy tie-up with Immaticshttps://pharmaphorum.com/news/gsk-begins-cancer-cell-therapy-tie-up-with-immatics/
